Bracco promotes MultiHance study results By AuntMinnieEurope.com staff writers
March 11, 2013 -- Bracco Diagnostics is highlighting results from a recent study that found a single, standard dose of its MultiHance MR contrast agent provided at least equivalent contrast enhancement and diagnostic performance to a double dose of gadopentetate dimeglumine (Gd-DTPA) in MR angiography (MRA) of the peripheral arteries.
In research published online January 31 in the Journal of Magnetic Resonance Imaging, lead author Dr. Jian Wang, from Shanghai Changhai Hospital, and colleagues shared results from a study that included 68 patients with peripheral arterial occlusive disease. All patients had two separate contrast-enhanced MRA exams, one with 0.1 mmoL/kg of MultiHance and one with a double dose (0.2 mmoL/kg) of Gd-DTPA.
Three radiologists blinded to patient information and contrast agent independently assessed the MRA images in terms of contrast enhancement, vessel anatomical delineation, and disease detection. The study showed no statistically significant difference between a single dose of MultiHance and a double dose of Gd-DTPA, according to Bracco.
Related Reading
Bracco acquires Swiss Medical Care, August 5, 2011 Bracco buys manufacturing facilities, May 23, 2011 Bracco revisits plans for U.S. launch of SonoVue, March 8, 2009 Bracco inks deal with Marillion, November 20, 2008 Bracco touts contrast study results, August 5, 2008
Copyright © 2013 AuntMinnieEurope.com
Last Updated np 3/13/2013 9:01:27 AM
|
|